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The paper by Bonello et al. (1), published in this issue of
the Journal, is the ﬁrst human study investigating the effect
of ticagrelor on adenosine plasma concentration in patients
with acute coronary syndrome.
Ticagrelor is a new antiplatelet drug directly blocking
P2Y12-adenosine diphosphate (ADP) receptors, which
show a better clinical proﬁle compared to clopidogrel in
patients with acute coronary syndrome (2). As for other
popular drugs, a “pleiotropic” non–platelet-directed property
has been suggested to explain the favorable clinical results.See page 872
Figure 1
Transthoracic Coronary Doppler Ultrasound in 78-kg
Patient With Normal LAD at Coronary Angiography
(Upper panels) Coronary ﬂow reserve of left anterior descending coronary artery
(LAD) elicited by standard adenosine dose (140 mg/kg over 2 min, corresponding
to a total dose of 22 mg). (Lower panels) Pre-medication with low-dose dipyr-
idamole (0.14 mg/kg over 1 min) followed by 4-min pause and low-dose adenosine
infusion (1 mg over 25 s), which is approximately one-ﬁfth of the standard dose,This work was inspired by 2 recently published reports
(3,4) supporting the hypothesis of an adenosine-mediated
or adenosine-like property of ticagrelor: an animal experi-
ment by van Giezen et al. (3) and a study on healthy
volunteers by Wittfeldt et al. (4).
Bonello et al. (1) hypothesize that the pleiotropic effect
of ticagrelor may be due to the physiological properties of
adenosine. In fact, adenosine increases coronary blood ﬂow
by a direct dilation of the microcirculation, which may play
a double role in coronary syndromes: 1) in the acute phase, it
may have a protective effect on ischemic myocardium (5);
and 2) in the long run, it may sustain stent patency.
In the study by Bonello et al. (1), patients receiving
ticagrelor had signiﬁcantly higher adenosine plasma
concentration compared to patients receiving clopidogrel.
Neither drug had a direct impact on adenosine receptors or
on cyclic adenosine monophosphate production, but it was
clear that ticagrelor inhibited adenosine reuptake by red
blood cells. Higher adenosine plasma concentration may
contribute to a better reﬂow, but also produces side effects*Editorials published in the Journal of the American College of Cardiology reﬂect the
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PLATO (Platelet Inhibition and Patient Outcomes) study,
are found more frequently with ticagrelor compared to clo-
pidogrel (2).
Therefore, it appears that oral administration of ticagrelor
mimics the effect of dipyridamole. Dipyridamole is a ﬁrst-
generation antiplatelet drug that also inhibits re-uptake
of adenosine. Adenosine is clinically used for interruption
of supraventricular tachycardia (6) and for measurement of
coronary artery ﬂow reserve with transthoracic coronary
Doppler ultrasound (7). Dipyridamole is also administered
during myocardial scintigraphy and stress echocardiography.
Dipyridamole is known since 1986 to strongly potentiate
the effects of adenosine, including its side effects (8,9). We
have conﬁrmed this interaction in our laboratory: in patients
pre-treated with very low–dose intravenous dipyridamole
(0.14 mg/kg over 1 min), a 4- to 5-fold dose reduction of
adenosine is sufﬁcient to elicit maximal coronary vasodila-
tion (unpublished data) (Fig. 1). Interestingly, even oral
administration of dipyridamole may potentiate the effect of
adenosine (8). In patients receiving dipyridamole, 1.0  0.52
mg adenosine was sufﬁcient to terminate supraventricular
tachycardia, whereas 8.8  2.6 mg was needed for patients
not receiving dipyridamole (8).
In addition to the important information on the possible
pleiotropic effect of ticagrelor related to adenosine concen-
tration, this work may have important implications in
our daily clinical practice. It may be hypothesized that
patients receiving either ticagrelor or dipyridamole may haveafter correction for the different time of administration (25 s vs. 2 min). At these
low doses, neither dipyridamole nor adenosine alone has any biological effect.
However, the infusion of low-dose adenosine after dipyridamole produces a similar
or even higher coronary hyperemic response compared to standard full-dose
adenosine infusion, demonstrating the strong potentiation effect of dipyridamole
on adenosine.
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879a supernormal response to standard adenosine doses used for
both therapeutic and diagnostic applications. For these
patients, we may suggest reducing the initial adenosine dose
4-fold to 5-fold, to prevent exaggerated side effects. In light
of this new important information, a warning may be sug-
gested regarding the use of adenosine for patients receiving
ticagrelor.
A ﬁnal note: Could the old, cheap, and neglected dipyr-
idamole have the same long-term effect on stent patency
as the new and expensive ticagrelor?
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